Development and Validation of a Nomogram to Predict Airway Fibrostenosis in Tracheobronchial Tuberculosis
Respiration · 2025
DOI: 10.1159/000548355 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Respiration, 2025. Verfasst von Wei Zhao und 13 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School, Guangzhou Medical University, Guangzhou, China. Hauptthemen laut MEDLINE: Nomograms, Tuberculosis, Pulmonary, Tracheal Diseases, Bronchial Diseases. Die Arbeit nennt 32 Literaturangaben.
Abstract (Originalsprache)
Introduction
Airway fibrostenosis, a severe complication of tracheobronchial tuberculosis (TBTB), causes respiratory morbidity including atelectasis, pneumonia, and respiratory failure. Early risk prediction remains challenging due to the lack of validated assessment tools.
Methods
This retrospective cohort study analyzed TBTB patients undergoing bronchoscopic interventions between January 2021 and June 2024 with 6-month follow-up. A Cox regression model was developed in all 305 patients, internally validated with 1,000 bootstrap resamples. Performance was evaluated via C-index, ROC-AUC, calibration, and decision curve analysis. Kaplan-Meier analysis was used to stratify groups, with log-rank tests assessing differences.
Results
Airway fibrostenosis incidence was 60.33% (184/305). Eight independent predictors were identified: symptom duration, affected lung lobes, diabetes, multiple TBTB types, bronchoscopic intervention frequency, initial sputum acid-fast bacilli smear grade, neutrophil-to-lymphocyte ratio, and CD8+ T-cell count. The nomogram demonstrated strong discrimination (C-index 0.77, 95% CI: 0.75–0.81) with increasing predictive accuracy over time: 6-week AUC 0.773 (0.708–0.838), 8-week 0.792 (0.740–0.844), 12-week 0.830 (0.782–0.878), and 16-week 0.883 (0.842–0.923). High-risk patients exhibited a significantly higher probability of developing airway fibrostenosis compared to low-risk patients (p < 0.001). Calibration and decision curve analyses confirmed clinical utility.
Conclusion
This validated nomogram effectively predicts airway fibrostenosis risk in TBTB patients, enabling early identification of high-risk individuals for targeted interventions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Graduate School, Guangzhou Medical University, Guangzhou, China.
- State Key Laboratory of Respiratory Disease, Guangzhou Key Laboratory of Tuberculosis Research, Endoscopy Center, Guangzhou Chest Hospital, Institute of Tuberculosis, Guangzhou Medical University, Guangzhou, China.
- State Key Laboratory of Respiratory Disease, Guangzhou Key Laboratory of Tuberculosis Research, Institute of Tuberculosis, Department of Tuberculosis, Guangzhou Chest Hospital, Guangzhou Medical University, Guangzhou, C…
- State Key Laboratory of Respiratory Disease, Guangzhou Key Laboratory of Tuberculosis Research, Institute of Tuberculosis, Department of Clinical Nutrition, Guangzhou Chest Hospital, Guangzhou Medical University, Guangz…
- School of Public Health, Guangzhou Medical University, Guangzhou, China.
Zitieren
APA
Zhao, W., Fang, W., Peng, D., Feng, Z., Wang, M., Zhang, H., Yuan, Y., Wu, D., Chen, Z., Huang, X., Yang, Z., Fan, J., Xiao, X., & Kuang, H. (2025). Development and Validation of a Nomogram to Predict Airway Fibrostenosis in Tracheobronchial Tuberculosis. Respiration. https://doi.org/10.1159/000548355
Vancouver
Zhao W, Fang W, Peng D, Feng Z, Wang M, Zhang H, et al. Development and Validation of a Nomogram to Predict Airway Fibrostenosis in Tracheobronchial Tuberculosis. Respiration. 2025. doi:10.1159/000548355
BibTeX
@article{Zhao2025,
author = {Zhao, Wei and Fang, Weiming and Peng, Dehu and Feng, Zhiyu and Wang, Min and Zhang, Hong and Yuan, Yuan and Wu, Di and Chen, Zeying and Huang, Xianlin and Yang, Zilong and Fan, Jiahua and Xiao, Xincai and Kuang, Haobin},
title = {Development and Validation of a Nomogram to Predict Airway Fibrostenosis in Tracheobronchial Tuberculosis},
journal = {Respiration},
year = {2025},
doi = {10.1159/000548355}
}
EUVIMED